Assessing the Protective Potential of H1N1 Influenza Virus Hemagglutinin Head and Stalk Antibodies in Humans

Abs targeting the HA head of influenza viruses are often associated with protection from influenza virus infections. These Abs typically have limited breadth, since mutations frequently arise in HA head epitopes. New vaccines targeting the more conserved HA stalk domain are being developed. Abs that target the HA stalk are protective in animal models, but it is unknown if these Abs exist at protective levels in humans. Here, we completed experiments to determine if Abs against the HA head and stalk were associated with protection from naturally acquired human influenza virus infections during the 2015–2016 influenza season. ABSTRACT Seasonal influenza viruses are a major cause of human disease worldwide. Most neutralizing antibodies (Abs) elicited by influenza viruses target the head domain of the hemagglutinin (HA) protein. Anti-HA head Abs can be highly potent, but they have limited breadth since the HA head is variable. There is great interest in developing new universal immunization strategies that elicit broadly neutralizing Abs against conserved regions of HA, such as the stalk domain. Although HA stalk Abs can provide protection in animal models, it is unknown if they are present at sufficient levels in humans to provide protection against naturally acquired influenza virus infections. Here, we quantified H1N1 HA head- and stalk-specific Abs in 179 adults hospitalized during the 2015–2016 influenza virus season. We found that HA head Abs, as measured by hemagglutinin inhibition (HAI) assays, were associated with protection against naturally acquired H1N1 infection. HA stalk-specific serum total IgG titers were also associated with protection, but this association was attenuated and not statistically significant after adjustment for HA head-specific Ab titers. We found slightly higher titers of HA stalk-specific IgG1 and IgA Abs in sera from uninfected participants than in sera from infected participants; however, we found no difference in serum in vitro antibody-dependent cellular cytotoxicity activity. In passive transfer experiments, sera from participants with high HAI activity efficiently protected mice, while sera with low HAI activity protected mice to a lower extent. Our data suggest that HA head Abs are more efficient at protecting against H1N1 infection than HA stalk Abs. IMPORTANCE Abs targeting the HA head of influenza viruses are often associated with protection from influenza virus infections. These Abs typically have limited breadth, since mutations frequently arise in HA head epitopes. New vaccines targeting the more conserved HA stalk domain are being developed. Abs that target the HA stalk are protective in animal models, but it is unknown if these Abs exist at protective levels in humans. Here, we completed experiments to determine if Abs against the HA head and stalk were associated with protection from naturally acquired human influenza virus infections during the 2015–2016 influenza season.

[1]  G. Pawelec Faculty Opinions recommendation of Assessing the protective potential of H1N1 influenza virus hemagglutinin head and stalk antibodies in humans. , 2020 .

[2]  M. Eichelberger,et al.  Evaluation of correlates of protection against influenza A(H3N2) and A(H1N1)pdm09 infection: Applications to the hospitalized patient population , 2018, bioRxiv.

[3]  R. Albrecht,et al.  A Live-Attenuated Prime, Inactivated Boost Vaccination Strategy with Chimeric Hemagglutinin-Based Universal Influenza Virus Vaccines Provides Protection in Ferrets: A Confirmatory Study , 2018, Vaccines.

[4]  J. Wrammert,et al.  Broadly Reactive Human Monoclonal Antibodies Elicited following Pandemic H1N1 Influenza Virus Exposure Protect Mice against Highly Pathogenic H5N1 Challenge. , 2018 .

[5]  D. Weissman,et al.  Nucleoside-modified mRNA vaccines induce potent T follicular helper and germinal center B cell responses , 2018, The Journal of experimental medicine.

[6]  J. Taubenberger,et al.  Evaluation of Preexisting Anti-Hemagglutinin Stalk Antibody as a Correlate of Protection in a Healthy Volunteer Challenge with Influenza A/H1N1pdm Virus , 2018, mBio.

[7]  T. Ross,et al.  Towards a universal influenza vaccine: different approaches for one goal , 2018, Virology Journal.

[8]  Seth J. Zost,et al.  Contemporary H3N2 influenza viruses have a glycosylation site that alters binding of antibodies elicited by egg-adapted vaccine strains , 2017, Proceedings of the National Academy of Sciences.

[9]  K. Subbarao,et al.  In Vitro Neutralization Is Not Predictive of Prophylactic Efficacy of Broadly Neutralizing Monoclonal Antibodies CR6261 and CR9114 against Lethal H2 Influenza Virus Challenge in Mice , 2017, Journal of Virology.

[10]  Catharine I Paules,et al.  The Pathway to a Universal Influenza Vaccine. , 2017, Immunity.

[11]  P. Palese,et al.  Influenza Virus Hemagglutinin Stalk-Specific Antibodies in Human Serum are a Surrogate Marker for In Vivo Protection in a Serum Transfer Mouse Challenge Model , 2017, mBio.

[12]  F. Krammer,et al.  Universal influenza virus vaccines and therapeutic antibodies. , 2017, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[13]  M. Kiso,et al.  A Broadly Reactive Human Anti-hemagglutinin Stem Monoclonal Antibody That Inhibits Influenza A Virus Particle Release , 2017, EBioMedicine.

[14]  Matthew Angel,et al.  Defining B Cell Immunodominance to Viruses , 2017, Nature Immunology.

[15]  Caitlin E. Mullarkey,et al.  Broadly Neutralizing Hemagglutinin Stalk-Specific Antibodies Induce Potent Phagocytosis of Immune Complexes by Neutrophils in an Fc-Dependent Manner , 2016, mBio.

[16]  W. Marasco,et al.  A broadly neutralizing anti-influenza antibody reveals ongoing capacity of haemagglutinin-specific memory B cells to evolve , 2016, Nature Communications.

[17]  A. Wilder-Smith,et al.  Randomized controlled trials for influenza drugs and vaccines: a review of controlled human infection studies. , 2016, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[18]  P. Palese,et al.  Age Dependence and Isotype Specificity of Influenza Virus Hemagglutinin Stalk-Reactive Antibodies in Humans , 2016, mBio.

[19]  R. Webby,et al.  The Hemagglutinin Stem-Binding Monoclonal Antibody VIS410 Controls Influenza Virus-Induced Acute Respiratory Distress Syndrome , 2016, Antimicrobial Agents and Chemotherapy.

[20]  P. Wilson,et al.  Germinal Center Selection and the Antibody Response to Influenza , 2015, Cell.

[21]  A. Monto,et al.  Antibody to Influenza Virus Neuraminidase: An Independent Correlate of Protection. , 2015, The Journal of infectious diseases.

[22]  Adrian Apetri,et al.  A stable trimeric influenza hemagglutinin stem as a broadly protective immunogen , 2015, Science.

[23]  J. Mascola,et al.  Hemagglutinin-stem nanoparticles generate heterosubtypic influenza protection , 2015, Nature Medicine.

[24]  Brantley R. Herrin,et al.  Lamprey VLRB response to influenza virus supports universal rules of immunogenicity and antigenicity , 2015, eLife.

[25]  Brantley R. Herrin,et al.  Author response: Lamprey VLRB response to influenza virus supports universal rules of immunogenicity and antigenicity , 2015 .

[26]  F. Hayden,et al.  Design, recruitment, and microbiological considerations in human challenge studies. , 2015, The Lancet. Infectious diseases.

[27]  Florian Krammer,et al.  Advances in the development of influenza virus vaccines , 2015, Nature Reviews Drug Discovery.

[28]  R. Davey,et al.  Validation of the wild-type influenza A human challenge model H1N1pdMIST: an A(H1N1)pdm09 dose-finding investigational new drug study. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[29]  P. Palese,et al.  Advances in the development of influenza virus vaccines , 2015, Nature Reviews Drug Discovery.

[30]  S. de Lusignan,et al.  Effectiveness of seasonal influenza vaccine in preventing laboratory-confirmed influenza in primary care in the United Kingdom: 2015/16 mid-season results. , 2015, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[31]  D. Skowronski,et al.  Interim estimates of 2014/15 vaccine effectiveness against influenza A(H3N2) from Canada's Sentinel Physician Surveillance Network, January 2015. , 2015, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[32]  Caitlin E. Mullarkey,et al.  Broadly Neutralizing Anti-Influenza Virus Antibodies: Enhancement of Neutralizing Potency in Polyclonal Mixtures and IgA Backbones , 2015, Journal of Virology.

[33]  Gillian Dekkers,et al.  IgG Subclasses and Allotypes: From Structure to Effector Functions , 2014, Front. Immunol..

[34]  J. Bloom,et al.  Potential antigenic explanation for atypical H1N1 infections among middle-aged adults during the 2013–2014 influenza season , 2014, Proceedings of the National Academy of Sciences.

[35]  I. Wilson,et al.  Characterization of a Broadly Neutralizing Monoclonal Antibody That Targets the Fusion Domain of Group 2 Influenza A Virus Hemagglutinin , 2014, Journal of Virology.

[36]  R. Cox,et al.  Serum IgG titres, but not avidity, correlates with neutralizing antibody response after H5N1 vaccination. , 2014, Vaccine.

[37]  T. Ross,et al.  Eliciting broadly protective antibody responses against influenza. , 2014, Current opinion in immunology.

[38]  A. Takada,et al.  Comparison of Antiviral Activity between IgA and IgG Specific to Influenza Virus Hemagglutinin: Increased Potential of IgA for Heterosubtypic Immunity , 2014, PloS one.

[39]  P. Palese,et al.  Broadly neutralizing hemagglutinin stalk–specific antibodies require FcγR interactions for protection against influenza virus in vivo , 2014, Nature Medicine.

[40]  Matthew S. Miller,et al.  Assessment of Influenza Virus Hemagglutinin Stalk-Based Immunity in Ferrets , 2014, Journal of Virology.

[41]  Antoine M. van Oijen,et al.  Mechanisms of Hemagglutinin Targeted Influenza Virus Neutralization , 2013, PloS one.

[42]  P. Palese,et al.  Expression of functional recombinant hemagglutinin and neuraminidase proteins from the novel H7N9 influenza virus using the baculovirus expression system. , 2013, Journal of visualized experiments : JoVE.

[43]  Florian Krammer,et al.  Influenza virus hemagglutinin stalk-based antibodies and vaccines. , 2013, Current opinion in virology.

[44]  R. Lamb,et al.  Textbook of Influenza , 2013 .

[45]  Nicole M. Bouvier,et al.  Recombinant IgA Is Sufficient To Prevent Influenza Virus Transmission in Guinea Pigs , 2013, Journal of Virology.

[46]  John J. Treanor,et al.  H3N2 Influenza Virus Infection Induces Broadly Reactive Hemagglutinin Stalk Antibodies in Humans and Mice , 2013, Journal of Virology.

[47]  N. S. Laursen,et al.  Highly Conserved Protective Epitopes on Influenza B Viruses , 2012, Science.

[48]  J. Ravetch,et al.  Mouse model recapitulating human Fcγ receptor structural and functional diversity , 2012, Proceedings of the National Academy of Sciences.

[49]  A. Jegerlehner,et al.  Universal vaccine against influenza virus: Linking TLR signaling to anti‐viral protection , 2012, European journal of immunology.

[50]  R. Albrecht,et al.  Influenza Viruses Expressing Chimeric Hemagglutinins: Globular Head and Stalk Domains Derived from Different Subtypes , 2012, Journal of Virology.

[51]  J. Oxford,et al.  Use of a human influenza challenge model to assess person-to-person transmission: proof-of-concept study. , 2011, The Journal of infectious diseases.

[52]  J. Skehel,et al.  A Neutralizing Antibody Selected from Plasma Cells That Binds to Group 1 and Group 2 Influenza A Hemagglutinins , 2011, Science.

[53]  Martin H. Koldijk,et al.  A Highly Conserved Neutralizing Epitope on Group 2 Influenza A Viruses , 2011, Science.

[54]  J. Yewdell,et al.  Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection , 2011, The Journal of experimental medicine.

[55]  David Baltimore,et al.  Permissive Secondary Mutations Enable the Evolution of Influenza Oseltamivir Resistance , 2010, Science.

[56]  K. Subbarao,et al.  Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine. , 2010, The Journal of clinical investigation.

[57]  John Steel,et al.  Influenza Virus Vaccine Based on the Conserved Hemagglutinin Stalk Domain , 2010, mBio.

[58]  R. Hai,et al.  Broadly Protective Monoclonal Antibodies against H3 Influenza Viruses following Sequential Immunization with Different Hemagglutinins , 2010, PLoS pathogens.

[59]  Gira Bhabha,et al.  Antibody Recognition of a Highly Conserved Influenza Virus Epitope , 2009, Science.

[60]  Boguslaw Stec,et al.  Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses , 2009, Nature Structural &Molecular Biology.

[61]  Y. Guan,et al.  Heterosubtypic Neutralizing Monoclonal Antibodies Cross-Protective against H5N1 and H1N1 Recovered from Human IgM+ Memory B Cells , 2008, PloS one.

[62]  Jessica M Malenfant,et al.  CD107a as a functional marker for the identification of natural killer cell activity. , 2004, Journal of immunological methods.

[63]  Niall Johnson,et al.  Updating the Accounts: Global Mortality of the 1918-1920 "Spanish" Influenza Pandemic , 2002, Bulletin of the history of medicine.

[64]  R. Webster,et al.  A DNA transfection system for generation of influenza A virus from eight plasmids. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[65]  J. Yewdell,et al.  The antigenic structure of the influenza virus A/PR/8/34 hemagglutinin (H1 subtype) , 1982, Cell.

[66]  R. Webster,et al.  Antigenic structure of influenza virus haemagglutinin defined by hybridoma antibodies , 1981, Nature.

[67]  A. S. Beare,et al.  The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses , 1972, Epidemiology and Infection.

[68]  T. Francis DISSOCIATION OF HEMAGGLUTINATING AND ANTIBODY-MEASURING CAPACITIES OF INFLUENZA VIRUS , 1946, The Journal of experimental medicine.

[69]  G. K. Hirst THE QUANTITATIVE DETERMINATION OF INFLUENZA VIRUS AND ANTIBODIES BY MEANS OF RED CELL AGGLUTINATION , 1942, The Journal of experimental medicine.

[70]  S. de Lusignan,et al.  Low effectiveness of seasonal influenza vaccine in preventing laboratory-confirmed influenza in primary care in the United Kingdom: 2014/15 mid-season results. , 2015, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.